RG
PLRX icon

Rathbones Group’s Pliant Therapeutics PLRX Stock Holding History

Rathbones Group’s Portfolio PLRX Stock Details PLRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-11,700
Closed -$174K – 636
2024
Q1 		$174K Hold
11,700
– – ﹤0.01% 558
2023
Q4 		$212K Hold
11,700
– – ﹤0.01% 527
2023
Q3 		$203K Buy
+11,700
New +$203K ﹤0.01% 537

Other funds holding PLRX

DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

Rathbones Group's PLRX Position: Q2 2024 in Review

Rathbones Group sold out of Pliant Therapeutics (PLRX) in Q2 2024, closing a stake of 11,700 shares — an estimated $174K sold.

Rathbones Group first reported a position in PLRX in Q3 2023 and held it in 3 quarters. The position peaked at $212K in Q4 2023. 143 funds tracked by Wall St. Rank hold PLRX as of Q2 2024.

  • Rathbones Group reported no remaining Pliant Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Rathbones Group sold 11,700 Pliant Therapeutics shares in Q2 2024, an estimated $174K.
  • Rathbones Group first reported a position in Pliant Therapeutics in Q3 2023 and held it in 3 quarters.
  • Rathbones Group's Pliant Therapeutics position peaked at $212K in Q4 2023.
  • 143 funds tracked by Wall St. Rank held Pliant Therapeutics as of Q2 2024.

Based on Rathbones Group's 13F filing for Q2 2024, filed 9 Aug 2024.